<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03041012</url>
  </required_header>
  <id_info>
    <org_study_id>eCLEAR-001</org_study_id>
    <secondary_id>2015-002234-53</secondary_id>
    <nct_id>NCT03041012</nct_id>
  </id_info>
  <brief_title>Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART</brief_title>
  <acronym>eCLEAR</acronym>
  <official_title>Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herning Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or
      administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent
      HIV-1 reservoir in treatment naïve HIV-1 patients initiating antiretroviral therapy (ART)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted among ART naïve HIV-1-infected patients.

      Subjects will continue ART while receiving LRA romidepsin and/or bNAb 3BNC117.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">August 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma HIV RNA kinetics</measure>
    <time_frame>3 months</time_frame>
    <description>Time to undetectable (&lt;20 c/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of the size of the proviral HIV reservoir</measure>
    <time_frame>1 year</time_frame>
    <description>Copies of total HIV-1 DNA per 10⁶ CD4+ T cells as measured by digital droplet PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emerging events (Safety and tolerability)</measure>
    <time_frame>1 year</time_frame>
    <description>Frequence and severity of adverse events (AE), adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and suspected unexpected serious adverse reactions (SUSAR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the integrated HIV DNA</measure>
    <time_frame>1 year</time_frame>
    <description>Integrated HIV-1 DNA in CD4+ T cells (copies per million cells) as measured by alu-PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the size of the replication-competent HIV reservoir</measure>
    <time_frame>1 year</time_frame>
    <description>The frequency of CD4+ T cells latently infected with replication competent HIV as measured by infectious units per million (IUPM) CD4+ T cells in a viral outgrowth assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>1 year</time_frame>
    <description>Absolute CD4+ and CD8+ T cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytic treatment interruption (ATI) study</measure>
    <time_frame>64 weeks</time_frame>
    <description>Time to plasma HIV RNA &gt;1000 c/mL on two consecutive measurements</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma cytokine and immune activation biomarker levels</measure>
    <time_frame>1 year</time_frame>
    <description>Soluble IL-6, sCD14, sCD163</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>antiretrovirals</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiretrovirals + romidepsin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care + LRA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiretrovirals + 3BNC117</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care + bNAb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiretrovirals + romidepsin + 3BNC117</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care + LRA + bNAb</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART</description>
    <arm_group_label>antiretrovirals + romidepsin</arm_group_label>
    <arm_group_label>antiretrovirals + romidepsin + 3BNC117</arm_group_label>
    <other_name>Istodax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3BNC117</intervention_name>
    <description>30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART</description>
    <arm_group_label>antiretrovirals + 3BNC117</arm_group_label>
    <arm_group_label>antiretrovirals + romidepsin + 3BNC117</arm_group_label>
    <other_name>Broadly neutralizing antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretrovirals</intervention_name>
    <description>Combination antiretroviral therapy</description>
    <arm_group_label>antiretrovirals</arm_group_label>
    <arm_group_label>antiretrovirals + romidepsin</arm_group_label>
    <arm_group_label>antiretrovirals + 3BNC117</arm_group_label>
    <arm_group_label>antiretrovirals + romidepsin + 3BNC117</arm_group_label>
    <other_name>ART</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  CD4+ T cell count &gt;200/µL on last visit prior to study entry

          -  ART naïve

          -  Able to give informed consent

        Exclusion Criteria:

          -  Any significant acute medical illness (not including primary HIV infection) in the
             past 8 weeks

          -  Any evidence of an active AIDS-defining opportunistic infection

          -  Active alcohol or substance use that, in the Investigator's opinion, will prevent
             adequate compliance with study therapy

          -  The following laboratory values at screening, but the values can be repeated within
             the screening period, but test results must be available before baseline (day 0) and
             checked for eligibility:

               -  Hepatic transaminases (AST or ALT) ≥3 x upper limit of normal (ULN)

               -  Serum total bilirubin ≥3 ULN

               -  Estimated glomerular filtration rate (eGFR) ≤60 mL/min (based on serum creatinine
                  or other appropriate validated markers)

               -  Platelet count ≤100 x10^9/L

               -  Absolute neutrophil count ≤1x10^9/L

               -  Serum potassium, magnesium, phosphorus outside ≥1.5 ULN/LLN

               -  Total calcium (corrected for serum albumin) or ionized calcium ≥1.5 ULN/LLN

               -  Hepatitis B or C infection as indicated by the presence of hepatitis B surface
                  antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood

          -  ECG at screening that shows QTc &gt;450 ms when calculated using the Fridericia formula
             from either lead V3 or V4 [86]

          -  Use of:

               -  Warfarin or warfarin-derivatives

               -  HDACi

               -  An agent definitely or possibly associated with effects on QT intervals within 2
                  weeks of screening

               -  Drugs that induce or inhibit CYP3A4 or P-gp

          -  History of:

               -  Clinically significant cardiac disease, symptomatic or asymptomatic arrhythmias,
                  syncopal episodes, or additional risk factors for Torsades de pointes (e.g. heart
                  failure)

               -  Malignancy or transplantation, including skin cancers or Kaposi sarcoma

               -  Diabetes mellitus

          -  Receipt of strong immunosuppressive or systemic chemotherapeutic agents within 28 days
             prior to study entry

          -  Known resistance to &gt;2 classes of ART

          -  Known hypersensitivity to the components of romidepsin, 3BNC117 or their analogues

          -  Women who are pregnant or breastfeeding, or with a positive pregnancy test during
             screening or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to
             use an acceptable method of non-estrogen containing contraceptions (according to the
             Danish Medicines Agency guidelines) to avoid pregnancy for the 3 week study period and
             4 weeks after study treatment or until undetectable plasma HIV-1 RNA using standard
             assays

          -  Males or females who are unwilling or unable to use barrier contraception during
             sexual intercourse for the 3-week study period, and 4 weeks after study treatment or
             until undetectable plasma HIV-1 RNA using standard assays
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole S Søgaard, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ole S Søgaard, MD PhD</last_name>
    <phone>+45 78452842</phone>
    <email>olesoega@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesper D Gunst, MD</last_name>
    <phone>+45 78452844</phone>
    <email>jesdam@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Infectious Diseases, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper d Gunst, MD</last_name>
      <phone>+45 78452844</phone>
      <email>jesdam@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Latency Reversal Agent</keyword>
  <keyword>Immunotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No plan available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

